Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    bet-at-home

    MCap

    EUR23m

    Last close

    EUR3.15

    ▲ 0.66 (26.51%)

    Metals One

    MCap

    GBP4m

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Avino Silver & Gold Mines

    MCap

    CAD533m

    Last close

    CAD3.76

    ▲ 0.53 (16.41%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Isofol Medical – executive interview

Isofol Medical – executive interview

In this interview with Petter Segelman Lindqvist, CEO of Isofol Medical, we discuss the company’s lead clinical programme, the mechanism of action of arfolitixorin and the recently announced rights issue. We also highlight the key catalysts that investors should watch out for in the year ahead.

Isofol Medical is a Sweden-based clinical-stage biotechnology company dedicated to improving prognoses for patients with severe forms of cancer. The company’s lead clinical candidate, arfolitixorin, is designed to increase the effect of standard treatments for several forms of solid tumours, with an initial focus on colorectal cancer. A Phase Ib/II trial is currently underway, following first patient dosing in April 2025.

< Previous
Next >

You may also be interested in these:

Healthcare

Mendus – executive interview

Healthcare

Herantis Pharma – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free